Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial

Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial

This trial in 1200 JE-vaccination naïve children (age 12–18 mo) in Thailand and the Philippines aimed to demonstrate consistency of three successive industrial scale manufacturing lots of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and consistency between industrial scale ma...

Full description

Saved in:
Bibliographic Details
Main Authors: Emmanuel Feroldi, Chitsanu Pancharoen, Pope Kosalaraksa, Veerachai Watanaveeradej, Kerdpanich Phirangkul, Maria R. Capeding, Mark Boaz, Sophia Gailhardou, Alain Bouckenooghe
Format: Article
Language:English
Published: Taylor & Francis Group 2012-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
safety
children
immunogenicity
Japanese encephalitis vaccine
phase 3 trial
Online Access:https://www.tandfonline.com/doi/10.4161/hv.20071
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items